Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:35:00 2024-04-23 am EDT			Pre-market 02:39:53 am
27.66 ^EUR	+1.02%		27.7	+0.14%

Apr. 23	FRESENIUS SE : Goldman Sachs sticks Neutral	ZD
Apr. 22	European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	MT

Fresenius : Jefferies Virtual London Healthcare Conference (PDF, 6.06 MB)

November 17, 2021 at 01:05 pm EST

12th Annual Jefferies London Healthcare Conference

November 18, 2021

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

12th Annual Jefferies London Healthcare Conference, November 18, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

Agenda

Company Highlights

02	03	04
Strategic update	Financial review	Attachments
	Q3/21 &
	Outlook FY/21

12th Annual Jefferies London Healthcare Conference, November 18, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

A Global Leader in Health Care Products and Services

in sales (FY/2020)

€ 36.3 bn

Global presence in 100+

countries

Leading market

#1 positions

Long-term opportunities in growing, non-cyclicalmarkets

100 +

Employees

worldwide

(as of September 30,

2021) 314,000+

Strong financial performance and cash flow generation

12th Annual Jefferies London Healthcare Conference, November 18, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

Investment Highlights

Diversified healthcare Group	Leading positions in	Resilient business model
with four strong business	growing non-cyclical	based on megatrends
segments	markets	healthcare and demographics

Purpose-driven business	Strong financial	Reliable
delivers sustainable	performance and cash	dividend growth
contribution to society	flow generation

12th Annual Jefferies London Healthcare Conference, November 18, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 17 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2021 17:59:14 UTC.

Latest news about Fresenius SE & Co. KGaA

FRESENIUS SE : Goldman Sachs sticks Neutral	Apr. 23	ZD
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	Apr. 22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	Apr. 22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	Apr. 22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	Apr. 22	ZD
Positive trend of FMC and Fresenius continues	Apr. 22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	Apr. 18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	Apr. 16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	Apr. 16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	Apr. 16	DP
Fresenius at two-month high - Tyenne launch a milestone	Apr. 16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Cannabis law and clinic atlas in the Bundesrat	Mar. 22	DP
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Criticism of hospital reform: 'Redistribution from the bottom to the top'	Mar. 20	DP
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ

Chart Fresenius SE & Co. KGaA

Duration

Period

More charts

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.66 EUR

Average target price

36.22 EUR

Spread / Average Target

+30.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-1.46%	16.67B
CVS HEALTH CORPORATION	-13.25%	86.34B
HCA HEALTHCARE, INC.	+18.01%	84.49B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.97%	29.68B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.50%	17.5B
EUROFINS SCIENTIFIC SE	+4.44%	12.71B
FRESENIUS MEDICAL CARE AG	+5.11%	12.53B
PURE HEALTH HOLDING	-30.53%	11.89B
DAVITA INC.	+27.83%	11.74B
UNIVERSAL HEALTH SERVICES, INC.	+8.18%	11.1B

Other Healthcare Facilities & Services